zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells

Int J Cancer. 1999 Oct 29;83(3):349-58. doi: 10.1002/(sici)1097-0215(19991029)83:3<349::aid-ijc10>3.0.co;2-c.

Abstract

We have observed that 2 forms of zonula occludens 2 (ZO-2) protein, ZO-2A and ZO-2C, are expressed in normal human pancreatic duct cells, but only ZO-2C in pancreatic duct adenocarcinoma. We report here partial organization of the zo-2 gene. Transcription of 2 forms of ZO-2 mRNA is driven by alternative promoters P(A) and P(C). Lack of expression of ZO-2A in neoplastic cells is caused by inactivation of the downstream promoter P(A). Analysis of the promoter P(A) sequence and function in normal and neoplastic cells demonstrated that neither structural changes (mutations) nor a change in the pool of transcription factors is responsible for its inactivation. Although hypermethylation was found in a large number of cancer clones, treatment with 5-aza-2'-deoxycytidine did not fully cause the promoter function to recover. We conclude that the initial down-regulation of zo-2 promoter P(A) activity in pancreatic duct carcinomas is due to the structural or functional alteration(s) in the regulatory elements, localized outside the analyzed promoter region. Methylation of P(A) is responsible for the inactivation of the suppressed promoter at the late stages of tumor development.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Base Sequence
  • DNA Methylation
  • Humans
  • Membrane Proteins / genetics*
  • Molecular Sequence Data
  • Pancreatic Ducts / metabolism*
  • Pancreatic Neoplasms / genetics*
  • Promoter Regions, Genetic*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Cells, Cultured
  • Zonula Occludens-2 Protein

Substances

  • Membrane Proteins
  • TJP2 protein, human
  • Zonula Occludens-2 Protein